Safiglipron OUTSTAND-2: The Oral GLP-1, No Fasting Rules

One of the most common reasons patients give up on oral semaglutide (Rybelsus) is not the medication itself — it is the rules that come with it. Take it on an empty stomach. Wait 30 minutes before eating, drinking anything besides water, or taking other pills. Build your morning around the tablet.

A phase 3 trial published October 5, 2026 in Nature Medicine tested a different kind of oral GLP-1 — one designed to be taken with no fasting window and no food-timing restrictions at all. The drug is called safiglipron, the trial is OUTSTAND-2, and the results are worth understanding carefully: both what they showed and what they did not.

This is a pipeline story, not an availability announcement. Safiglipron is not approved in the United States, and there is no way to obtain it through legitimate care today. Here is what the study actually found.

What OUTSTAND-2 Actually Tested

OUTSTAND-2 was a phase 3, multicenter, randomized, double-blind, double-dummy, active-comparator-controlled trial conducted at 98 sites in China. It enrolled 810 adults with type 2 diabetes whose blood sugar was inadequately controlled on metformin alone. Participants were randomized to one of four daily tablets for 32 weeks, followed by a 20-week active-treatment extension:

• Safiglipron 30 mg
• Safiglipron 60 mg
• Safiglipron 90 mg
• Dapagliflozin 10 mg (an approved SGLT2 inhibitor used as the comparator)

The sponsor is Jiangsu Hengrui Pharmaceuticals, and the drug's patent is still pending. The primary endpoint was the change in HbA1c (a three-month average blood sugar measure) from baseline to week 32.

What the Data Showed

All three safiglipron doses met the trial's primary goal. On the pre-specified non-inferiority comparison, safiglipron performed at least as well as dapagliflozin on HbA1c at every dose tested — in fact, the numerical differences favored safiglipron at all three doses, with confidence intervals excluding zero.

Only the highest dose went further. Under a second, more conservative way of analyzing the same data (the treatment-policy estimand), the 90 mg dose met the criterion for superiority over dapagliflozin. The 60 mg dose did not, and the pre-planned testing sequence stopped there.

A meaningful share of patients reached target ranges. Between roughly 55 and 63 percent of safiglipron patients reached an HbA1c below 7.0 percent, versus about 37 percent on dapagliflozin; the gap widened further at the stricter 6.5 percent threshold.

The most patient-relevant finding was not on the chart of blood sugar numbers at all: safiglipron is an oral small-molecule GLP-1 receptor agonist taken without fasting or dietary restrictions. That is the design feature OUTSTAND-2 put to the test in a phase 3 setting for the first time.

What the Data Did Not Show

This is where coverage of the trial tends to go wrong, so it is worth being precise.

No comparison against any GLP-1. The comparator was dapagliflozin, an SGLT2 inhibitor — a completely different drug class. OUTSTAND-2 did not test safiglipron against semaglutide, oral or injectable, or against any other incretin-based therapy. Non-inferiority to an SGLT2 inhibitor is not the same as matching semaglutide.

No weight-loss win. Mean body weight change over 32 weeks was about −2.4 percent, −3.6 percent, and −4.2 percent for safiglipron 30, 60, and 90 mg respectively — versus about −3.6 percent for dapagliflozin. The highest safiglipron dose did not beat the SGLT2 comparator on weight, which is notable given how central weight outcomes are to the GLP-1 story.

Gastrointestinal side effects were more common with safiglipron. They were mostly rated mild to moderate, but discontinuation due to adverse events ran around 4 percent across safiglipron doses versus 1.5 percent for dapagliflozin.

The population was type 2 diabetes patients in China on metformin. The trial did not enroll people using GLP-1 therapy primarily for weight management, and all sites were in China. Generalizing these results to other populations or treatment goals is an inference, not a finding.

How Safiglipron Differs From Oral Semaglutide and Orforglipron

All three are pills, but they are not interchangeable.

Oral semaglutide (Rybelsus) is a peptide GLP-1 delivered in a tablet — and the only oral GLP-1 currently approved in the US. Its absorption depends on a strict empty-stomach protocol: taken first thing in the morning with no more than a few ounces of water, then nothing else by mouth for 30 minutes. Many patients manage this fine; many others find it impractical, and adherence suffers. Our overview of the current oral GLP-1 pill landscape covers what is actually available today.

Orforglipron is a small-molecule GLP-1 — like safiglipron, it is designed to be absorbed regardless of food, so no fasting window is required. It is far along in development for both diabetes and weight management, and has been the presumptive "next pill" in most patient-facing coverage. If you are weighing today's approved injectable options instead, our semaglutide vs tirzepatide comparison breaks down the practical differences.

Safiglipron is the newest entrant: a small-molecule GLP-1 that now has a positive phase 3 readout against an active comparator. The practical difference from Rybelsus is the fasting protocol — there isn't one. The scientific difference from orforglipron is simply that this is a different molecule from a different sponsor, and each will stand or fall on its own trial program.

For context on where safiglipron sits in the broader research pipeline, including other next-generation candidates, see our next-gen GLP-1 pipeline explainer.

When Might It Reach US Patients?

Realistically: not soon, and possibly never without more trials.

Every step between a phase 3 publication and a pharmacy shelf is a separate hurdle. Safiglipron would need to complete its full clinical development program, file for regulatory approval in the US, and receive it — a process measured in years even when it goes smoothly. The sponsor is a Chinese pharmaceutical company (Jiangsu Hengrui), the completed trial sites were all in China, and the compound's patent is still pending — all of which add uncertainty to a US timeline that does not publicly exist yet. And even positive phase 3 data in type 2 diabetes would not automatically support approval for weight management; that indication requires its own evidence.

If you are considering GLP-1 therapy today, the realistic options remain the approved medications — injectable semaglutide and tirzepatide, and oral semaglutide with its timing requirements. Our guide to choosing the best GLP-1 for weight loss walks through how those decisions actually get made. For patients in the Dallas–Fort Worth and North Texas area, a GLP-1 program consultation with a licensed prescriber is the right next step — not a waitlist for a drug that has not been filed anywhere.

All therapy decisions belong with your prescriber, who knows your history, your other medications, and your goals. Nothing here is medical advice, and nothing here should change a treatment plan.

Frequently Asked Questions

What is safiglipron?

Safiglipron is an investigational oral small-molecule GLP-1 receptor agonist developed by Jiangsu Hengrui Pharmaceuticals. Unlike the currently approved oral semaglutide (Rybelsus), it is designed to be taken without fasting or food-timing restrictions.

What did the OUTSTAND-2 trial find?

In this phase 3 trial of 810 adults with type 2 diabetes in China, all three safiglipron doses (30, 60, and 90 mg daily) met the primary goal of non-inferiority on HbA1c reduction versus dapagliflozin at 32 weeks, and the 90 mg dose met the criterion for superiority under a stricter analysis. Gastrointestinal side effects were more common with safiglipron and were mostly mild to moderate.

Is safiglipron better than semaglutide?

That comparison has not been tested. OUTSTAND-2 compared safiglipron against dapagliflozin, an SGLT2 inhibitor from a different drug class. No published trial has compared safiglipron head-to-head against semaglutide or any other GLP-1 medication.

Can I get safiglipron in the US?

No. Safiglipron is investigational: it is not approved by the FDA, has no US filing announced, and was studied only at trial sites in China. Any offer to sell it today would not be a legitimate medication source.

How is safiglipron different from oral semaglutide?

The main practical difference is the dosing routine. Oral semaglutide requires an empty-stomach protocol with a 30-minute wait before food, drink, or other medications; safiglipron is designed to be taken without those restrictions. It also remains investigational, while oral semaglutide is FDA-approved.

When could safiglipron become available?

There is no announced timeline. Between a phase 3 publication and pharmacy availability sit the remainder of the clinical program, a regulatory submission, and an approval decision — each a multi-step process measured in years, with additional uncertainty from the pending patent and the China-only trial footprint.